The EpiVax team had a great time in Tokyo hosting the Westin Immunogenicity Seminar! Please see pictures from the event below. Stay tuned for dates/details for 2023!


The EpiVax team is pleased to share a new date for the 14th Annual Westin Tokyo Seminar, Friday September 9th, 2022.

The Westin Tokyo
1 Chome-4-1 Mita, Meguro
Tokyo, Japan 153-8580

The Westin Immunogenicity Seminar is a unique forum for industry and academic professionals to share ideas, present research updates, and network with potential collaborators.

In addition, there will be a networking cocktail hour for those interested.

The purpose of this seminar is to bridge the gap between protein drug development and recent academic research on Tregs, Tregitopes, with a special focus on immunogenicitydeimmunization, and tolerance induction.

Discussion topics are to include:

  • Determinants of immunogenicity
  • Induction of tolerance
  • Measuring and modulating immunogenicity
  • Immunogenicity and tolerance in immuno-oncology applications

This year we are honored to include Dr. Amy Rosenberg as our keynote speaker. You are probably already familiar with Dr. Rosenberg, who is a 20-year veteran of the FDA’s Division of Therapeutic Proteins, CDER, oversaw the regulation and approval of numerous protein therapeutics and served as the FDA’s expert consultant to the National Institute of Health’s Immune Tolerance Network. She also served on the cross-disciplinary team for cancer immunotherapy. Her work and her talk focus on immune tolerance induction and immunogenicity.

Dr. Guilhem Richard from EpiVax Therapeutics will also attend this meeting and will be presenting on the topics of personalized cancer vaccines and neoantigen design. Dr. Richard brings a wealth of bioinformatics knowledge specifically for immuno-onocology applications. He has been an integral part of the team that developed the Ancer toolkit for improved neoantigen selection for personalized cancer vaccine candidates.

Confirmed Speakers 

Annie De Groot, MD
Research Professor, Center for Vaccines and Immunology, University of Georgia
CEO/CSO, EpiVax, Inc.

Amy Rosenberg, MD
Senior Director of Immunology and Protein Therapeutics, EpiVax, Inc.

Dr. Guilhem Richard
Chief Technology Officer, EpiVax Therapeutics

Dr. Masahiro Isogawa
Laboratory Chief, National Institute of Infectious Diseases (NIID)

Dr. Susumu Uchiyama
Professor, Osaka University

Dr. Hiroaki Suga
Professor, University of Tokyo & Executive Officer, MiraBiologics